Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer
December 8, 2016 7:04 pmAvastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.
The approval … Read more